article thumbnail

FDA Approves Omalizumab to Reduce Food-Based Allergic Reactions in Adult and Pediatric Patients

Pharmacy Times

This marks omalizumab’s fourth FDA-approved indication for allergic and inflammatory conditions, such as severe persistent allergic asthma, with its initial approval being in 2003.

Food 57
article thumbnail

470% price increases

World of DTC Marketing

Today, AbbVie charges approximately $77,000 for a year’s supply of Humira—470% more than when the drug was launched in 2003. Today, Imbruvica is priced at $181,529 per year for a patient taking three pills per day, compared to $99,776 per year at launch. net revenue from Humira.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Globus Medical and NuVasive to Combine in All-Stock Transaction to Create Innovative Global Musculoskeletal Company Focused on Patient Care

Legacy MEDSearch

The transaction brings together two well-regarded technology companies in the musculoskeletal industry, which have a shared vision focused on innovation in a relentless pursuit of unmet clinical needs to improve patient care. ” About Globus Medical Globus Medical is a leading musculoskeletal solutions company based in Audubon, PA.

Medical 98
article thumbnail

COVID-19: Some ignored facts

World of DTC Marketing

Since there have been no major outbreaks of SARS since 2003, testing vaccine efficacy was difficult. At a local hospital in Michigan all cases of patients admitted for COVID are patients under 40 who have not been vaccinated. Funding was not the only issue.

article thumbnail

Ex-Theranos CEO Elizabeth Holmes sentenced to 11 years

pharmaphorum

Holmes – who is heavily pregnant and was in tears whilst addressing during the sentencing hearing – said she felt ” deep shame for what people went through because I failed them”, apologising to both investors and patients. “I regret my failings with every cell of my body,” she continued.

FDA 100
article thumbnail

Economist Impact: World Cancer Series – pharmaphorum in attendance, day one (part i)

pharmaphorum

It is, she said, the uniting of industry with researchers and researchers with patients, and so forth, that is at the heart of this journey currently being undertaken. What will then be provided will be personalised cancer care for EU patients. Essentially, The Code is there for the entire cancer patient journey.

article thumbnail

Drug developers look at innovative mechanisms to tackle dry eye syndrome

Pharmaceutical Technology

Dry eye syndrome (DES) is an indication whose mainstay treatment has been dominated by Allergan’s Restasis (cyclosporine ophthalmic emulsion 0.05%) ever since its launch in 2003 in the US. NOV-03 is also likely to be well-received by physicians and patients due to its favorable clinical and tolerability profile.